22 / 25
Page 86
conferenceseries
.com
Volume 8
Journal of Gastrointestinal & Digestive System
ISSN: 2161-069X
Bariatric Surgery 2018 & Gastro 2018
March 15-16, 2018
JOINT EVENT
12
th
Global Gastroenterologists Meeting
3
rd
International Conference on Metabolic and Bariatric Surgery
&
March 15-16, 2018 Barcelona, Spain
Analysis of serum chromogranin A in irritable bowel syndrome and gastroenteropancreatic
neuroendocrine tumors patients in Indonesia
Alya Darin Wijaya
1,2
, Daniel Martin Simadibrata
1,2
Tutug Kinasih
1,2
and
Murdani Abdullah
1,2
1
Universitas Indonesia, Indonesia
2
RSUPN Dr. Cipto Mangunkusumo National Central General Hospital, Indonesia
C
hromograninA(CgA), an acidic hydrophilic glycoproteinproduced exclusively by the secretory granules of neuroendocrine
cells, is found to be increased in gastroenteropancreatic neuroendocrine tumors (GEP-NET) cases. Previous studies show
that CgA has a high sensitivity as a serum biomarker in diagnosing GEP-NET. However, it has a low specificity since it is
also increased in other conditions, such as irritable bowel syndrome (IBS). Diagnosis of GEP-NET through CgA serum level
measurement has not been performed in Indonesia. Hence, this study aims to compare plasma CgA levels among normal
patients, GEP-NET patients, and IBS patients in Indonesia. A cross-sectional study was performed among 176 individuals who
had undergone Gastroenterology Consultation of which 126 patients were normal, 21 patients were IBS, and 29 patients were
GEP-NET. IBS patients were identified using ROME III Criteria and GEP-NET patients were identified through histopathology
examination fromGI (Gastrointestinal) tract biopsy. Blood plasma serumwas taken to measure the CgA serum level. Statistical
analysis was performed using Kruskal-Wallis test. CgA serum levels were found to be significantly higher in both IBS and GEP-
NET group compared to those in normal group. The average CgA serum levels in IBS, GEP-NET, and normal group are 76.66,
173.78, and 50.72 with the median 64.82, 66.23, and 48.90 respectively. The CgA value between normal and GEP-NET or IBS
group is found to be significantly different (p<0.001). CgA serum levels remain a reliable biomarker to diagnose GEP-NET,
suggesting the use of CgA for screening GEP-NET in Indonesia. However, the rise in CgA level found in IBS patients speculates
future possibilities of developing GEP-NET in IBS patients. Further studies need to be performed to determine the relationship
between IBS and GEP-NET, in terms of CgA.
ialyaone@gmail.comJ Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C1-065